Cognition Therapeutics (CGTX)
(Delayed Data from NSDQ)
$1.93 USD
-0.06 (-3.02%)
Updated Apr 25, 2024 03:59 PM ET
After-Market: $1.93 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Cognition Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -25.79 | -21.40 | -11.72 | -7.84 | NA |
Depreciation/Amortization & Depletion | 0.25 | 0.24 | 0.48 | 0.93 | NA |
Net Change from Assets/Liabilities | 4.85 | -0.94 | 2.84 | 3.07 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 4.67 | 3.57 | 4.77 | 0.41 | NA |
Net Cash From Operating Activities | -16.02 | -18.53 | -3.63 | -3.43 | NA |
Property & Equipment | -0.15 | -0.17 | -0.03 | -0.01 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Investing Activities | -0.15 | -0.17 | -0.03 | -0.01 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 5.33 | 6.94 | 44.53 | 0.05 | NA |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 8.94 | 5.37 | NA |
Increase (Decrease) Short-Term Debt | -0.81 | -1.40 | -0.27 | 0.00 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.35 | NA |
Net Cash from Financing Activities | 4.52 | 5.55 | 53.20 | 5.77 | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | -0.01 | -0.02 | NA |
Net Change In Cash & Equivalents | -11.64 | -13.16 | 49.53 | 2.30 | NA |
Cash at Beginning of Period | 41.56 | 54.72 | 5.19 | 2.89 | NA |
Cash at End of Period | 29.92 | 41.56 | 54.72 | 5.19 | NA |
Diluted Net EPS | -0.86 | -0.91 | -3.13 | NA | NA |
Fiscal Year End for Cognition Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -25.79 | -17.65 | -10.90 | -6.17 |
Depreciation/Amortization & Depletion | NA | 0.25 | 0.19 | 0.12 | 0.06 |
Net Change from Assets/Liabilities | NA | 4.85 | 3.29 | 1.85 | 1.90 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 4.67 | 3.61 | 2.53 | 1.51 |
Net Cash From Operating Activities | NA | -16.02 | -10.56 | -6.40 | -2.71 |
Property & Equipment | NA | -0.15 | -0.12 | -0.06 | -0.04 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.15 | -0.12 | -0.06 | -0.04 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 5.33 | 2.71 | 2.50 | 0.00 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | -0.81 | -0.63 | -0.42 | -0.01 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 4.52 | 2.08 | 2.09 | -0.01 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -11.64 | -8.59 | -4.37 | -2.75 |
Cash at Beginning of Period | NA | 41.56 | 41.56 | 41.56 | 41.56 |
Cash at End of Period | NA | 29.92 | 32.97 | 37.19 | 38.81 |
Diluted Net EPS | NA | -0.27 | -0.22 | -0.16 | -0.21 |